Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Federal Court Overturns Gilead Sciences and Merck Patent Dispute

  • Post author:Sam
  • Post published:February 19, 2018
  • Post category:BioPharma

Federal court judge orders Merck to repay $2.5 Billion to Gilead in overturned patent decision. Source: BioSpace

Continue ReadingFederal Court Overturns Gilead Sciences and Merck Patent Dispute

AbbVie and Voyager Therapeutics Launch $1.2 Billion+ Alzheimer’s Partnership

  • Post author:Sam
  • Post published:February 19, 2018
  • Post category:BioPharma

AbbVie and Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases. Source: BioSpace

Continue ReadingAbbVie and Voyager Therapeutics Launch $1.2 Billion+ Alzheimer’s Partnership

J&J Could Explore Potential $2B Sale of Sterilization Products Division

  • Post author:Sam
  • Post published:February 19, 2018
  • Post category:BioPharma

Life sciences giant Johnson & Johnson may be shopping around its sterilization products division. Source: BioSpace

Continue ReadingJ&J Could Explore Potential $2B Sale of Sterilization Products Division

PDL BioPharma Gives Up on Acquiring Neos Therapeutics

  • Post author:Sam
  • Post published:February 19, 2018
  • Post category:BioPharma

Nevada-based PDL BioPharma, Inc. said it will no longer pursue a proposed acquisition of Neos Therapeutics. Source: BioSpace

Continue ReadingPDL BioPharma Gives Up on Acquiring Neos Therapeutics

AbbVie Presents New Phase 2b Data on Upadacitinib in Atopic Dermatitis

  • Post author:Sam
  • Post published:February 18, 2018
  • Post category:BioPharma

AbbVie today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis. Source:…

Continue ReadingAbbVie Presents New Phase 2b Data on Upadacitinib in Atopic Dermatitis

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçe…

  • Post author:Sam
  • Post published:February 18, 2018
  • Post category:BioPharma

RELIEF™ trial demonstrated statistically significant reductions in oral ulcers with apremilast 30 mg versus placebo through week 12. Source: BioSpace

Continue ReadingOTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçe…

AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab…

  • Post author:Sam
  • Post published:February 18, 2018
  • Post category:BioPharma

AbbVie presented today new positive results from the pivotal Phase 3 ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety and efficacy of risankizumab (150 mg) compared to placebo…

Continue ReadingAbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab…

Why Novavax Could be a Millionaire-Maker Stock

  • Post author:Sam
  • Post published:February 15, 2018
  • Post category:BioPharma

If you had a crystal ball, you probably would have invested in Berkshire Hathaway in 1964, or Apple in the 1980s. Source: BioSpace

Continue ReadingWhy Novavax Could be a Millionaire-Maker Stock

Russia Allegedly Behind Merck's Cyberattack Last Year

  • Post author:Sam
  • Post published:February 15, 2018
  • Post category:BioPharma

Government officials say they are now certain they know who launched the NotPetya cyberwar that slammed operations at Merck last year. Source: BioSpace

Continue ReadingRussia Allegedly Behind Merck's Cyberattack Last Year

FDA Advisory Panel Spurns Pacira's Request for Expanded Use of Pain Drug Exparel

  • Post author:Sam
  • Post published:February 15, 2018
  • Post category:BioPharma

Shares of Pacira plunged more than 15 percent this morning after the company revealed the FDA panel's decision. Source: BioSpace

Continue ReadingFDA Advisory Panel Spurns Pacira's Request for Expanded Use of Pain Drug Exparel
  • Go to the previous page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.